Sarepta Therapeutics, Inc.
SRPT· Nasdaq
SRPTSarepta Therapeutics, Inc.
Filed Feb 28, 2023 · 10-K · 59 days after period end · 0000950170-23-005062
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $235.93M | $178.73M | $122.64M | $100.11M |
| Net Income | -$109.24M | -$121.98M | -$189.32M | -$235.70M |
| EPS Diluted | — | — | -$2.40 | -$3.16 |
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Feb 28, 2023 · 59 d after period end
